Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

PaperCitations, authors & open-access status

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 435 citations, 2023 year and green oa status.

435
Citations
2023
Year
green
OA Status

Related on ScholarIQ

Manabu Morimoto
Author
The Lancet Oncology
Journal
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Topic
Liver physiology and pathology
Topic
470M+ articles · free account